Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035945 · ClinicalTrials.gov registry record · Phase 2
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00035945: Completed Phase 2 study, sponsored by Ionis Pharmaceuticals.
NCT00035945 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035945, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
Interventions
- DRUG ISIS 14803
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10-01 |
| Est. Completion | 2004-05-01 |
| Phase | Phase 2 |
What the finished NCT00035945 record still lists
NCT00035945 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ISIS 14803 is the first listed.
NCT00035945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035945 about?
NCT00035945 is a clinical study titled "ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections". Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
What is the current status of trial NCT00035945?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-10-01. Estimated completion is 2004-05-01.
What interventions are being tested in trial NCT00035945?
The interventions under investigation include: ISIS 14803 (DRUG).
Who is sponsoring clinical trial NCT00035945?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI